Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT03017937 |
Other study ID # |
2016-8580 |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
November 2016 |
Est. completion date |
June 2019 |
Study information
Verified date |
October 2020 |
Source |
Children's Hospital Medical Center, Cincinnati |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Clinical trials have suggested that this device is effective in mitigating changes in brain
structure and function in athlete populations. The purpose of the current study is to measure
the response of the jugular vein to various pressures applied by a generic compression device
across various ages and gender. The relative jugular vein response will be measured using
ultrasound.
Description:
The Device has the promise of providing a novel mechanism for reducing or preventing the
likelihood of TBI, and may be used in conjunction with other protective equipment. TBI is the
leading cause of death in individuals under age 45. The cost of TBI in the U.S. is estimated
at anywhere from $50 to $150 billion, annually. Concussion in female high school soccer
players have been noted to occur at a rate of 4.5 concussions per 10,000 athletic exposures
(Comstock, Currie et al. 2015). The investigators propose that Slosh Theory can explain these
differences offering a mechanistic approach that could help shed light on further ways to
alleviate the TBI burden on society. Note that Slosh Theory teaches that hydrodynamics
(fluids moving within moving containers) contribute to, or are even the main etiology for,
energy absorption of the cranial contents and that mitigation of SLOSH (increased
compensatory reserve volume) may mitigate TBI. Significant morbidity, mortality, and related
costs are caused by traumatic brain injury (TBI). A simple, effective, and lightweight device
worn by athletes or war fighters in the field, designed to mitigate TBI resulting from blast
trauma or concussive events, would save lives, and the huge costs currently being experienced
for life-treatment of surviving victims. An externally-worn medical device (the Device) that
applies mild jugular vein compression according to the principle of the Queckenstedt
Maneuver, is being developed by Q30 Sports Science, LLC (Q30). Preliminary research suggests
that the Device has the potential to reduce the likelihood of TBI. The currently developed
collar (Smith 2009, Smith and Fisher 2011, Smith and Fisher 2011, Smith 2012) has been
approved for studies in humans (IRB 2013-2240) and the results indicate safety for use during
high demand and maximal exertion activities. Regarding safety, the externally worn collar is
meticulously designed to mimic the body's own omohyoid muscle actions upon the jugular veins
that will provide similar pressure and volume increases not to surpass that of a yawn or the
mere act of just lying down. Initial safety testing and early clinical trials indicate that
the collar application is both safe and efficacious to prevent brain microstructure and
neurophysiological changes in response to head impacts.